GRCE

#4305
Grace Therapeutics, Inc. - Common Stock
2.1 2 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.12
2.12
Intervallo Annuale
1.79
5.18
Variazione giornaliera
-1.85%
Variazione Mensile
+0.95%
Variazione di 6 mesi
-50.12%
Variazione Annuale
-46.73%
Chiusura Precedente
2.1 6
Open
2.1 2
Minimo
2.1 2
Massimo
2.1 2
Volume
2
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Grace Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Grace Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Grace Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q1 FY2027
Grace Therapeutics, Inc. quarterly report, Q1 FY2027
10-Q
Current report, Q2 FY2026
Grace Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Grace Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Grace Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Grace Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Grace Therapeutics, Inc. current report, Q2 FY2026
8-K
Annual report, FY2026
Grace Therapeutics, Inc. annual report, FY2026
10-K

Grace Therapeutics, Inc. current report, Q3 FY2024

Full document

Business Context and Reporting Period

This Form 8-K reports on events occurring on September 30, 2024, regarding Acasti Pharma Inc. (trading symbol: ACST). The filing details the results of the Company's Annual and Special Meeting of Shareholders. Note: The request metadata references "Grace Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Acasti Pharma Inc.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.

Material Changes and Voting Results

Shareholders representing 70.50% of outstanding common shares (7,149,326 shares) participated in the meeting. All six proposals were approved:

  • Election of Directors: Vimal Kavuru, A. Brian Davis, S. George Kottayil, Prashant Kohli, and Edward Neugeboren were elected.
  • Independent Auditor: KPMG was appointed as the independent registered public accounting firm.
  • Executive Compensation: The advisory vote to approve named executive officer compensation passed.
  • Corporate Restructuring (Continuance): Shareholders approved the continuance of the Company from the Province of Québec to the Province of British Columbia.
  • Corporate Restructuring (Domestication): Shareholders approved the domestication of the Company from British Columbia to the State of Delaware.
  • Equity Incentive Plan: The Acasti Pharma Inc. 2024 Equity Incentive Plan was approved, conditional upon the domestication resolution.

Guidance, Outlook, and Risks

The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the standard disclosures regarding the corporate restructuring. The domestication to Delaware and the approval of the new equity plan are contingent upon the successful completion of the continuance to British Columbia.

Investor Verification Checklist

  • Verify the legal status of the company following the approved domestication to Delaware.
  • Review the full text of the 2024 Equity Incentive Plan (Exhibit 10.1) for share reserve limits and vesting terms.
  • Confirm the effective date of the change in jurisdiction from Québec to British Columbia to Delaware.
  • Check subsequent filings for the appointment of the new board of directors and any changes to executive compensation structures.